Radiogenomics Consortium (RGC)
- Organizational Structure
- Funding Sources
- Consortium Publications
The Radiogenomics Consortium was established in November 2009. The scientific hypothesis underlying the development of the consortium is that a cancer patient's likelihood of developing toxicity to radiation therapy is influenced by common genetic variations, such as single nucleotide polymorphisms (SNPs).
The Consortium members undertake collaborative projects to identify SNPs associated with adverse effects following radiotherapy, share data and samples, perform meta-analyses, and work together to submit research grant applications.
The objectives of the Radiogenomics Consortium are to expand knowledge of the genetic basis for differences in radiosensitivity and to develop assays to help predict the susceptibility of cancer patients for the development of adverse effects resulting from radiotherapy, through:
- Fostering international collaborative research projects in radiogenomics through sharing of biospecimens and data;
- Developing guidelines to improve the standardization of radiogenomics research;
- Providing a framework for the efficient conduct and publication of original data meta-analyses of relevant studies;
- Providing a forum and framework for discussion, development and pursuit of new research directions; and
- Supporting the development of early career researchers.
A Coordinating Committee was established to run the Consortium. The lead coordinators for the Radiogenomics Consortium are Barry Rosenstein, Ph.D., of Icahn School of Medicine at Mount Sinai, New York, and Catharine West, Ph.D., of the University of Manchester, UK.
Other members of the Committee are:
- Nicolaj Andreassen, M.D., Ph.D., of Aarhus University, Denmark
- Gill Barnett, B.M., B.Ch., Ph.D., of University of Cambridge, UK
- Soeren Bentzen, Ph.D., D.Sc., of University of Wisconsin, USA
- Jenny Chang-Claude, Ph.D., of German Cancer Research Center (DKFZ)
- Joe Deasy,Ph.D., of Memorial Sloan-Kettering Cancer Center, New York
- Alison Dunning, Ph.D., of University of Cambridge, UK
- Sarah Kerns, Ph.D., MPH, of Icahn School of Medicine at Mount Sinai Medicine, New York
The Committee also includes representatives from the NCI, including Nonniekaye Shelburne, C.R.N.P., M.S., A.O.C.N.; Daniela Seminara, Ph.D., M.P.H.; and Eric DeRycke, M.P.H.
Lynda Rath of Icahn School of Medicine at Mount Sinai and Rebecca Elliot, of the University of Manchester provide administrative support.
As of May 2013, membership of the Radiogenomics Consortium consists of about 150 individuals located at more than 80 institutions in 19 countries.
The Radiogenomics Consortium is open to all investigators interested in studying the relationship between genetic variation and radiation therapy toxicity.
Anyone interested in joining RGC should email Lynda Rath.
Support for logistical needs of the Consortium has been provided by NCI's Epidemiology and Genomics Research Program (EGRP) in the Division of Cancer Control and Population Sciences (DCCPS) and the Radiation Research Program (RRP) in the Division of Cancer Treatment and Diagnosis (DCTD). Many members of the RGC are principal or co-investigators for grants that support research in radiogenomics and receive funding from National Cancer Institute, European Commission, Cancer Research UK, Canadian Institutes of Health, US Department of Defense, Deustsche Krebshilfe e.V, Health Research Fund, National Science Centre, and Spanish Ministry of Health.
- Kerns SL, Stock R, Stone N, Buckstein M, Shao Y, Campbell C, Rath L, De Ruysscher D, Lammering G, Hixson R, Cesaretti J, Terk M, Ostrer H, Rosenstein BS. 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e21-8.
- Barnett GC, Elliott RM, Alsner J, Andreassen CN, Abdelhay O, Burnet NG, Chang-Claude J, Coles CE, Gutiérrez-Enríquez S, Fuentes-Raspall MJ, Alonso-Muñoz MC, Kerns S, Raabe A, Symonds RP, Seibold P, Talbot CJ, Wenz F, Wilkinson J, Yarnold J, Dunning AM, Rosenstein BS, West CM, Bentzen SM. Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiother Oncol. 2012 Dec;105(3):289-95.
- Talbot CJ, Tanteles GA, Barnett GC, Burnet NG, Chang-Claude J, Coles CE, Davidson S, Dunning AM, Mills J, Murray RJ, Popanda O, Seibold P, West CM, Yarnold JR, Symonds RP. A replicated association between polymorphisms near TNFα and risk for adverse reactions to radiotherapy. Br J Cancer. 2012 Aug 7;107(4):748-53. doi: 10.1038/bjc.2012.290. Epub 2012 Jul 5. PMID:22767148
- West C, Rosenstein BS, Alsner J, Azria D, Barnett G, Begg A, Bentzen S, Burnet N, Chang-Claude J, Chuang E, Coles C, De Ruyck K, De Ruysscher D, Dunning A, Elliott R, Fachal L, Hall J, Haustermans K, Herskind C, Hoelscher T, Imai T, Iwakawa M, Jones D, Kulich C; EQUAL-ESTRO, Langendijk JH, O'Neils P, Ozsahin M, Parliament M, Polanski A, Rosenstein B, Seminara D, Symonds P, Talbot C, Thierens H, Vega A, West C, Yarnold J. Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1295-6.
- West C, Rosenstein BS. Establishment of a radiogenomics consortium. Radiother Oncol. 2010 Jan;94(1):117-8.
The Radiogenomics Consortium organizes annual meetings. The 2013 meeting will be in Cambridge, UK, October 16-17. Anyone interested in joining or attending the RGC annual meeting should e-mail Lynda Rath.
The 2012 conference was a pre-meeting of the American Society for Radiation Oncology (ASTRO) annual meeting in Boston in November.
- Barry Rosenstein, Ph.D.
Icahn School of Medicine at Mount Sinai
- Catharine West, Ph.D.
University of Manchester
- Nonniekaye Shelburne, C.R.N.P., M.S., A.O.C.N.
- Daniela Seminara, Ph.D., M.P.H.
Scientific Consortia Coordinator
- Eric DeRycke, M.P.H.